Clinical Trial Update: Rebif® Rebidose® Versus Rebiject II® Ease-of-Use [Phase 4]

View source ↗

Summary

Phase 4 trial comparing Rebif Rebidose to Rebiject II for ease of use in patients with relapsing-remitting multiple sclerosis; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: EMD Serono | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Status: COMPLETED | Results posted: 2017-03-07